

In the Claims:

1-118. Canceled.

119. (Currently amended) An isolated nucleic acid encoding a polypeptide having at least 80% ~~nucleic acid~~ sequence identity to:

- (a) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
- (e) ~~the nucleic acid sequence shown in Figure 271 (SEQ ID NO: 376);~~
- (f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or
- (g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;

wherein said encoded polypeptide is an immunosuppressor.

120. (Currently amended) An isolated nucleic acid of Claim 119 encoding a polypeptide having at least 85% ~~nucleic acid~~ sequence identity to:

- (a) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;
- (c) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
- (d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~

- (e) ~~the nucleic acid sequence shown in Figure 271 (SEQ ID NO: 376);~~
(f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or
(g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said encoded polypeptide is an immunosuppressor.

121. (Currently amended) An isolated nucleic acid of Claim 119 encoding a polypeptide having at least 90% ~~nucleic acid~~ sequence identity to:

- (a) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
(b) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;
(e) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
(d) ~~a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
(e) ~~the nucleic acid sequence shown in Figure 271 (SEQ ID NO: 376);~~
(f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or
(g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said encoded polypeptide is an immunosuppressor.

122. (Currently amended) An isolated nucleic acid of Claim 119 encoding a polypeptide having at least 95% ~~nucleic acid~~ sequence identity to:

- (a) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
(b) ~~a nucleic acid sequence encoding the~~ amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;

- ~~(e) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
 - ~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
 - ~~(e) the nucleic acid sequence shown in Figure 271 (SEQ ID NO: 376);~~
 - ~~(f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or~~
 - ~~(g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;~~
- wherein said encoded polypeptide is an immunosuppressor.

123. (Currently amended) An isolated nucleic acid of Claim 119 encoding a polypeptide having at least 99% ~~nucleic acid~~ sequence identity to:

- ~~(a) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377);~~
 - ~~(b) a nucleic acid sequence encoding the amino acid sequence of the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
 - ~~(e) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
 - ~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
 - ~~(e) the nucleic acid sequence shown in Figure 271 (SEQ ID NO: 376);~~
 - ~~(f)(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or~~
 - ~~(g)(d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;~~
- wherein said encoded polypeptide is an immunosuppressor.

124. (Currently amended) An isolated nucleic acid comprising:

- (a) a nucleic acid sequence encoding the polypeptide of shown in Figure 272 (SEQ ID NO: 377);
- (b) a nucleic acid sequence encoding the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;
- ~~(e) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377);~~
- ~~(d) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide;~~
- ~~(e)(c)~~ the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376);
- ~~(f)(d)~~ the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376); or
- ~~(g)(e)~~ the full-length coding sequence of the cDNA deposited under ATCC accession number 203092.

125. (Currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 272 (SEQ ID NO: 377).

126. (Currently amended) The isolated nucleic acid of Claim 124 comprising a nucleic acid sequence encoding the polypeptide of shown in Figure 272 (SEQ ID NO: 377), lacking its associated signal peptide.

127-128. Canceled.

129. (Currently amended) The isolated nucleic acid of Claim 124 comprising the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376).

130. (Currently amended) The isolated nucleic acid of Claim 124 comprising the full-length coding sequence of the nucleic acid sequence of shown in Figure 271 (SEQ ID NO: 376).

131. (Previously presented) The isolated nucleic acid of Claim 124 comprising the full-length

coding sequence of the cDNA deposited under ATCC accession number 203092.

132-134. (Canceled)

135. (Currently amended) A vector comprising the nucleic acid of Claim 119 or 139.

136. (Previously presented) The vector of Claim 135, wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

137. (Currently amended) A An isolated host cell comprising the vector of Claim 135.

138. (Previously presented) The host cell of Claim 137, wherein said cell is a CHO cell, an *E. coli* or a yeast cell.

139. (New) An isolated nucleic acid encoding a polypeptide having at least 80% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 376; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092; wherein said encoded polypeptide induces chondrocyte redifferentiation.

140. (New) An isolated nucleic acid encoding a polypeptide according to Claim 139 having at least 85% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377, lacking its associated signal peptide;

- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 376; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said encoded polypeptide induces chondrocyte redifferentiation.

141. (New) An isolated nucleic acid encoding a polypeptide according to Claim 139 having at least 90% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 376; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said encoded polypeptide induces chondrocyte redifferentiation.

142. (New) An isolated nucleic acid encoding a polypeptide according to Claim 139 having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 376; or
- (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
wherein said encoded polypeptide induces chondrocyte redifferentiation.

143. (New) An isolated nucleic acid encoding a polypeptide according to Claim 139 having at least 99% sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 377;
 - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 377, lacking its associated signal peptide;
 - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the nucleic acid sequence of SEQ ID NO: 376; or
 - (d) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203092;
- wherein said encoded polypeptide induces chondrocyte redifferentiation.